Reportable
18 May 2023, 23:38 GMT+10
Edmonton, Alberta, Canada/May 18, 2023- Pacylex Pharmaceuticals, a clinical-stage company developing PCLX-001, a first-in-class oral investigational small molecule for leukemia, lymphoma, and solid tumor cancers, today announced the first patient has been dosed in a Phase 2a expansion study in patients with relapsed/refractory B-cell Non-Hodgkin Lymphoma (R/R NHL).
To view the full announcement, including downloadable images, bios, and more, click here.
Click image above to view full announcement.
About PCLX-001PCLX-001 is a first-in-class, oral, small molecule N-myristoyltransferase (NMT) inhibitor being developed to treat patients with leukemia and lymphoma. PCLX-001 selectively kills cancer cells in vitro and have been shown to regress hematologic malignancies and inhibit the growth of lung and breast cancer tumors in animal models. PCLX-001 appears to be particularly effective against Acute Myeloid Leukemia (AML) stem cells in animal disease models. The Phase 1/2a study (NCT04836195) is an open-label study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of PCLX-001 in patients with R/R NHL and advanced solid malignancies who have progressed on all available standard therapies.
About Pacylex PharmaceuticalsPacylex is a clinical-stage pharmaceutical company headquartered in Edmonton, Alberta, Canada, targeting hematologic and solid cancers with a first-in-class, oral, once daily investigational therapeutic, PCLX-001. Pacylex has a US Subsidiary in the San Francisco Bay area. PCLX-001 is the lead drug in a new class of NMT inhibitors, enabling Pacylex to exploit NMTs as new clinical targets for cancer treatment. Pacylex is conducting a multi-center Phase 1 multiple ascending dose study in Canada in patients with R/R NHL and advanced solid tumors, and a Phase 2a dose expansion in patients with R/R NHL. The US Department of Defense is supporting the initial clinical investigation of PCLX-001 in patients with AML. The FDA has granted PCLX-001 both Orphan Drug Designation and Fast Track Designation for AML. Pacylex received support from an Alberta Innovates AICE grant in 2020, and the research leading to this breakthrough was supported in part by the Alberta Cancer Foundation and the Cure Cancer Foundation.
For additional information, please visit www.pacylex.com.
Contacts:Pacylex Pharmaceuticals: Michael J. WeickertCEO, Pacylex Pharmaceuticals, Inc.E: michael.weickert@pacylex.comP: 650-218-1840Twitter @Pacylex (https://twitter.com/pacylex) LinkedIn (www.linkedin.com/company/pacylex-pharma)Facebook (https://www.facebook.com/pacylex)Reportable page: (https://pacylex.reportablenews.com/)#cancer, #lymphoma, #leukemia, #albertacancer, #Pacylex, #PCLX001, #UAlberta; #UAlberta_FoMD; #Worldslongestgame, #ASH22, #MDACC, #NH
Michael Weickert Ph.D
650-218-1840
Source: Pacylex
Distributed by: Reportable, Inc.
Get a daily dose of Calgary Monitor news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Calgary Monitor.
More InformationMENLO PARK, California: Facebook parent Meta has said that under a trial that could last through the end of June, ...
Washington [US], June 9 (ANI): Cuba has agreed to allow China to construct a surveillance facility on the island that ...
Zack Wheeler took a no-hitter into the eighth inning, yet it took a game-ending single from Kody Clemens in the ...
New York [US], June 9 (ANI): Former President Donald Trump has been indicted in an investigation into his handling of ...
The idea that PGA Tour players who did not defect to LIV Golf should receive some sort of compensation is ...
New Delhi [India], June 9 (ANI): Referring to the controversial video of a parade in Canada's Brampton depicting the assassination ...
MENLO PARK, California: Facebook parent Meta has said that under a trial that could last through the end of June, ...
MOSCOW, Russia: Journalists from countries that are "unfriendly" to Russia will be banned from covering this year's St. Petersburg International ...
Brandon Belt hit the go-ahead single in a three-run fifth inning and the Toronto Blue Jays defeated the visiting Houston ...
Zack Wheeler took a no-hitter into the eighth inning, yet it took a game-ending single from Kody Clemens in the ...
The idea that PGA Tour players who did not defect to LIV Golf should receive some sort of compensation is ...
New Delhi [India], June 9 (ANI): Referring to the controversial video of a parade in Canada's Brampton depicting the assassination ...